The USA’s Merck & Co (NYSE: MRK) has suffered a setback for its star immuno-oncology therapy Keytruda (pembrolizumab), in gastric cancer.
The firm says an analysis of top-line results from the Phase III KEYNOTE-062 trial, which is evaluating the drug as both monotherapy and in combination with chemotherapy, missed key primary endpoints related to efficacy.
Merck is hoping to develop the therapy as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze